Pfizer Inc. (PFE)
| Market Cap | 125.57B |
| Revenue (ttm) | 63.63B |
| Net Income (ttm) | 8.03B |
| Shares Out | 5.67B |
| EPS (ttm) | 1.41 |
| PE Ratio | 15.70 |
| Forward PE | 7.52 |
| Dividend | $1.72 (7.77%) |
| Ex-Dividend Date | Jan 24, 2025 |
| Volume | 54,070,612 |
| Open | 22.20 |
| Previous Close | 22.04 |
| Day's Range | 22.11 - 22.55 |
| 52-Week Range | 20.92 - 31.54 |
| Beta | 0.60 |
| Analysts | Hold |
| Price Target | 30.86 (+39.35%) |
| Earnings Date | Apr 29, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for PFE stock is "Hold." The 12-month stock price forecast is $30.86, which is an increase of 39.35% from the latest price.
News
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield
Pfizer has faced headwinds post-COVID, but remains a key player with a robust R&D pipeline and an attractive 7.5%+ dividend yield. The pharmaceutical industry thrives on high R&D investment and patent...
ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand ...
Pfizer: Tasty 7% Yield
Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. The biopharma has a robust pipeline with potential mega blockbuster cancer drugs a...
Trump signs healthcare executive order that includes a win for pharma companies
U.S. President Donald Trump directed his health department on Tuesday to work with Congress on revamping a law that allows Medicare to negotiate prescription drug prices, seeking to introduce a change...
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in w...
European pharma companies issue demands to stay in EU ahead of expected US tariffs
Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, inclu...
Tariffs on generic drugs will cause companies to stop making them: Former FDA Commissioner Gottlieb
Dr. Scott Gottlieb, former FDA Commissioner, joins 'Squawk Box' to discuss current pharmaceutical imports under investigation, moving production for branded and generic drugs elsewhere, and much more.
The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now
Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields appro...
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'
Pfizer (PFE) said it will stop development of an oral daily weight-loss pill after a participant taking the drug in a clinical trial experienced a liver injury.
Pfizer ends development of weight-loss pill danuglipron
Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved after the medica...
Pfizer scraps daily weight loss pill after liver injury in one patient
Pfizer said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient's liver enzy...
Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant
Danuglipron was the latest drug investors were hinging hope on to enter the obesity market.
Pfizer Halts Development of New Weight-Loss Drug
The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which...
3 Dividend Stocks for April 2025
This month's trio includes two dividend aristocrats.
Buy 9 'Safer' Dividend Dogs Of 23 April Barron's Better Bets Than T-Bills
Nine out of ten "Safest" BBB dividend dogs are ready to buy, with annual dividends from $1K invested exceeding single share prices. Analysts expect 32.86% to 53.48% net gains from top-ten BBB dogs by ...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT o...
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturin...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
